Skip to main content
Premium Trial:

Request an Annual Quote

EraGen Wins $100K NIH Grant to Develop Bioterror Tests

NEW YORK, Aug. 27 - EraGen Biosciences said it has been awarded a $100,000 grant from the US National Institutes of Health to develop tests to detect single copies of certain bioweapon agents.


EraGen said it will use its GeneCode technology to test for the existence of so-called Category A organisms, like Bacillus anthracis. R&D work on the tests began earlier this month and will continue for two years, the company said.


Click here for more information.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.